The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zerafa, N.
Right arrow Articles by Smyth, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zerafa, N.
Right arrow Articles by Smyth, M. J.
The Journal of Immunology, 2005, 175: 5586-5590.
Copyright © 2005 by The American Association of Immunologists


CUTTING EDGE

Cutting Edge: TRAIL Deficiency Accelerates Hematological Malignancies1

Nadeen Zerafa2,*, Jennifer A. Westwood2,*, Erika Cretney*, Sally Mitchell*, Paul Waring{dagger}, Manuela Iezzi{ddagger} and Mark J. Smyth3,*

* Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; {dagger} Pathology and Diagnostics, Genentech Incorporated, South San Francisco, CA 94080; and {ddagger} Aging Research Center, G. D’Annunzio University Foundation, Chieti, Italy

TNF apoptosis-inducing ligand is attracting considerable interest as a potential extrinsic tumor suppressor mechanism, although previous reports have conveyed somewhat contrasting views regarding the likely importance of this pathway. In this study, we provide the first evaluation of spontaneous tumor formation over the life span of TRAIL-deficient mice. Interestingly, >25% of these mice do develop lymphoid malignancies after 500 days of life. TRAIL suppressed the initiation and development of both tumors of lymphoid and stromal origin in the context of the loss of at least one p53 allele. Specific examination of the role of TRAIL in Her2/neu oncogene-driven mammary epithelial cancer revealed no critical role for TRAIL despite the inherent TRAIL sensitivity of such mammary carcinomas. Overall, the data indicate an important function of TRAIL in controlling carcinogenesis, but suggest that further examination of this pathway in epithelial malignancies is warranted.




This article has been cited by other articles:


Home page
BloodHome page
K. H. Young, D. D. Weisenburger, B. J. Dave, L. Smith, W. Sanger, J. Iqbal, E. Campo, J. Delabie, R. D. Gascoyne, G. Ott, et al.
Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma
Blood, December 15, 2007; 110(13): 4396 - 4405.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Vitovski, J. S. Phillips, J. Sayers, and P. I. Croucher
Investigating the Interaction between Osteoprotegerin and Receptor Activator of NF-{kappa}B or Tumor Necrosis Factor-related Apoptosis-inducing Ligand: EVIDENCE FOR A PIVOTAL ROLE FOR OSTEOPROTEGERIN IN REGULATING TWO DISTINCT PATHWAYS
J. Biol. Chem., October 26, 2007; 282(43): 31601 - 31609.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Bin, J. Thorburn, L. R. Thomas, P. E. Clark, R. Humphreys, and A. Thorburn
Tumor-derived Mutations in the TRAIL Receptor DR5 Inhibit TRAIL Signaling through the DR4 Receptor by Competing for Ligand Binding
J. Biol. Chem., September 21, 2007; 282(38): 28189 - 28194.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. Yang, N. ud Din, D. D. Browning, S. I. Abrams, and K. Liu
Targeting Lymphotoxin {beta} Receptor with Tumor-Specific T Lymphocytes for Tumor Regression
Clin. Cancer Res., September 1, 2007; 13(17): 5202 - 5210.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. E.A. Street, N. Zerafa, M. Iezzi, J. A. Westwood, J. Stagg, P. Musiani, and M. J. Smyth
Host Perforin Reduces Tumor Number but Does Not Increase Survival in Oncogene-Driven Mammary Adenocarcinoma
Cancer Res., June 1, 2007; 67(11): 5454 - 5460.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. F. Gajewski
On the TRAIL Toward Death Receptor-Based Cancer Therapeutics
J. Clin. Oncol., April 10, 2007; 25(11): 1305 - 1307.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.